These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20530289)

  • 1. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
    Hu J; Handisides DR; Van Valckenborgh E; De Raeve H; Menu E; Vande Broek I; Liu Q; Sun JD; Van Camp B; Hart CP; Vanderkerken K
    Blood; 2010 Sep; 116(9):1524-7. PubMed ID: 20530289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
    Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
    Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
    Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
    Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
    Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
    PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
    Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
    Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition.
    Yamazaki H; Lai YC; Tateno M; Setoguchi A; Goto-Koshino Y; Endo Y; Nakaichi M; Tsujimoto H; Miura N
    PLoS One; 2017; 12(5):e0177305. PubMed ID: 28489881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302.
    Lohse I; Rasowski J; Cao P; Pintilie M; Do T; Tsao MS; Hill RP; Hedley DW
    Oncotarget; 2016 Jun; 7(23):33571-80. PubMed ID: 27248663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.
    Takakusagi Y; Kishimoto S; Naz S; Matsumoto S; Saito K; Hart CP; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2018 Jan; 28(2):131-140. PubMed ID: 28741367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
    Asosingh K; De Raeve H; de Ridder M; Storme GA; Willems A; Van Riet I; Van Camp B; Vanderkerken K
    Haematologica; 2005 Jun; 90(6):810-7. PubMed ID: 15951294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302.
    Saggar JK; Tannock IF
    Clin Cancer Res; 2015 May; 21(9):2107-14. PubMed ID: 25677696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma.
    Jardim-Perassi BV; Mu W; Huang S; Tomaszewski MR; Poleszczuk J; Abdalah MA; Budzevich MM; Dominguez-Viqueira W; Reed DR; Bui MM; Johnson JO; Martinez GV; Gillies RJ
    Theranostics; 2021; 11(11):5313-5329. PubMed ID: 33859749
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.
    Liapis V; Labrinidis A; Zinonos I; Hay S; Ponomarev V; Panagopoulos V; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
    Cancer Lett; 2015 Feb; 357(1):160-169. PubMed ID: 25444931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
    Bailey KM; Cornnell HH; Ibrahim-Hashim A; Wojtkowiak JW; Hart CP; Zhang X; Leos R; Martinez GV; Baker AF; Gillies RJ
    PLoS One; 2014; 9(12):e113586. PubMed ID: 25532146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
    Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
    BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.
    Meng F; Evans JW; Bhupathi D; Banica M; Lan L; Lorente G; Duan JX; Cai X; Mowday AM; Guise CP; Maroz A; Anderson RF; Patterson AV; Stachelek GC; Glazer PM; Matteucci MD; Hart CP
    Mol Cancer Ther; 2012 Mar; 11(3):740-51. PubMed ID: 22147748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
    Liapis V; Zysk A; DeNichilo M; Zinonos I; Hay S; Panagopoulos V; Shoubridge A; Difelice C; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
    Cancer Med; 2017 Sep; 6(9):2164-2176. PubMed ID: 28799237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
    Hong CR; Wilson WR; Hicks KO
    Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
    Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
    [No Abstract]   [Full Text] [Related]  

  • 20. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
    Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
    Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.